Michele Figus
Michele Figus is an expert in Ophthalmology at University of Pisa (Italy). As of October 2026, ScienceLeadR ranks Michele Figus in the top 1% of experts worldwide for Glaucoma and Ocular Hypertension. Michele Figus has authored 242 publications, the most recent in 2026, and is an investigator in 6 clinical trials. SLR score: 696 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Endocrinology - Biochemistry - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 242
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Thyroid eye disease. PMID 42537765 — eye, vision, ocular, pharmaceutical preparations, thyroid gland, graves disease, graves ophthalmopathy, eye diseases, therapeutics, exophthalmos, autoimmunity | Autoimmun Rev | 2026 | 0 |
| The Behavior of the External Limiting Membrane and Ellipsoid Zone in Diabetic Macular Edema: A Population AI-Assisted Optical Coherence Tomography Study. PMID 42765790 — eye, ophthalmology, tomography, biomarkers, macular edema, visual acuity, tomography, optical coherence, artificial intelligence, retinaldehyde, membranes, edema | Invest Ophthalmol Vis Sci | 2026 | 0 |
| Unraveling the effects of glycerophosphoinositol-enriched hyaluronic acid eyedrops on the ocular surface in glaucoma: a report from the multicenter OSGLA registry. PMID 42625741 — registries, eye, sexually transmitted diseases, hyaluronic acid, glaucoma, matrix metalloproteinases, therapeutics | Front Med (Lausanne) | 2026 | 0 |
| Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trial. PMID 42247155 — eye, levofloxacin, ophthalmology, ketorolac, conjunctivitis, bacterial, conjunctivitis, bacteria | Graefes Arch Clin Exp Ophthalmol | 2026 | 0 |
| Two-years efficacy and safety of bleb forming devices in uncontrolled glaucoma. PMID 42008153 — safety, ophthalmology, blister, glaucoma | Graefes Arch Clin Exp Ophthalmol | 2026 | 0 |
Clinical Studies 6
LeadR Networks
Main global connection map